Welcome to our dedicated page for Immucell SEC filings (Ticker: ICCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImmuCell filings document material events and governance matters for an animal health biologics company built around First Defense. Form 8-K reports record preliminary and annual financial results, board retirements and appointments, senior-officer employment agreements, and settlement of claims tied to a prior development services and commercial supply agreement.
Definitive proxy materials cover director matters, board oversight, executive compensation, and equity-award disclosures. The filing record also includes exhibits with company press releases addressing product sales, financial condition, strategic focus, and related operating updates.
ImmuCell Corporation reported strong first-quarter 2026 results, highlighted by double-digit growth and improved profitability. Product sales rose 28.4% to $10.4 million, lifting gross margin to 45.0%. Net income increased to $1.9 million, or $0.21 per share, compared with $1.4 million, or $0.16 per share, a year earlier.
The company generated $3.4 million of free cash flow, raising cash to $6.8 million as of March 31, 2026, while maintaining solid inventory. ImmuCell also received a net $2 million payment from settling disputes with a former contract manufacturer and increased manufacturing output from about 380,000 to more than 450,000 units per month.
ImmuCell Corporation reported strong first-quarter 2026 growth, with higher sales and profitability. Product sales reached $10.36 million, up 28.4% from $8.07 million a year earlier, driven mainly by higher volumes and price increases in its First Defense® line. Net income rose to $1.94 million from $1.45 million, and basic and diluted earnings per share increased to $0.21 from $0.16. Gross profit improved to $4.66 million as cost of goods sold grew more slowly than revenue, helped by price actions and manufacturing efficiencies. Operating cash flow more than doubled to $3.57 million, boosting cash and cash equivalents to $6.81 million while total debt edged down to $8.70 million. The company also changed useful-life estimates on certain idle Re-Tain® assets, reducing quarterly depreciation by about $0.1 million. After quarter-end, ImmuCell entered a Settlement Deed under which Norbrook Laboratories agreed to pay $2.0 million, resolving a prior development and supply agreement.
ImmuCell Corporation filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to update the exhibit list only. The amendment adds a previously filed Loan Agreement with Maine Community Bank as Exhibit 10.43, corrects and clarifies descriptions and “incorporated by reference” notations for several executive compensation and plan documents, and refiles the 2025 Stock Option and Incentive Plan to match the version in the April 24, 2026 proxy statement. Updated CEO and CFO certifications are also included. The company states that its audited financial statements and other disclosures from the original filing are unchanged.
ImmuCell Corporation entered into a new settlement agreement with Norbrook Laboratories on May 8, 2026. The companies signed a Settlement Deed that resolves and releases all claims related to their 2019 Development Services and Commercial Supply Agreement, which expired March 31, 2026. Under this Settlement Deed, Norbrook will pay ImmuCell $2,000,000, providing a one-time cash benefit to ImmuCell. The agreement is governed by Northern Ireland law, contains confidentiality undertakings, and explicitly states it is not an admission of liability or wrongdoing by either party.
ImmuCell Corporation is asking stockholders to vote at its June 11, 2026 virtual annual meeting. Holders of 9,046,799 common shares as of April 13, 2026 can elect seven directors, cast an advisory “say-on-pay” vote, and ratify Wipfli LLP as auditor.
Stockholders are also asked to approve the 2025 Stock Option and Incentive Plan, which authorizes up to 650,000 shares and has 403,777 options already granted, largely contingent on approval, and to amend the charter to add Delaware-permitted officer exculpation.
The proxy highlights a leadership transition to new CEO P. Olivier te Boekhorst, a strategic focus on the First Defense® product line, efforts to partner Re-Tain®, creation of a Strategy & Technology Committee, and updated compensation and equity policies for executives and directors.
ImmuCell Corp. director Anthony DiMarco filed an initial ownership report showing a holding of non-qualified stock options. These options cover 17,899 shares of common stock at an exercise price of $7.60 per share and expire on April 15, 2036.
The options vest over three years: 5,966 shares become exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares on April 15, 2029. This filing records DiMarco’s derivative equity position; it does not show any recent buy or sell transaction.
ImmuCell Corp (ICCC) director Gilles Guillemette filed an initial Form 3 reporting stock option holdings. The filing shows non-qualified stock options to acquire 17,899 shares of common stock at an exercise price of $7.60 per share, expiring on April 15, 2036.
The options vest in three equal annual installments: 5,966 shares become exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares become exercisable on April 15, 2029. All reported holdings are owned directly.
ImmuCell Corporation director Kathy V. Turner received a grant of 17,899 non-qualified stock options. These options give her the right to buy an equal number of ImmuCell common shares at an exercise price of $7.60 per share and represent a compensation award rather than an open-market purchase.
The options vest over three years, with 5,966 options becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 options vesting on April 15, 2029. All of the options expire on April 15, 2036 if they are not exercised.
ImmuCell Corp director David Scott Tomsche received a grant of stock options as part of his compensation. He was awarded 11,933 non-qualified stock options to buy ImmuCell common stock at an exercise price of $7.60 per share, expiring on April 15, 2036.
The options vest over time: 3,977 become exercisable on April 15, 2027, another 3,977 on April 15, 2028, and 3,979 on April 15, 2029. This is a compensation-related award, not an open-market purchase or sale of shares.
ImmuCell director Gloria F. Basse received a grant of 11,933 non-qualified stock options to buy ImmuCell common stock. The options have an exercise price of $7.60 per share and expire on April 15, 2036.
All 11,933 options were awarded as compensation and are held directly. According to the vesting schedule, 3,977 options become exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 options become exercisable on April 15, 2029.